Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

New HIV Drugs - Pifeltro® and Delstrigo®

Monday 15 October 2018

Two new HIV medications have been added to the interaction checker. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and was approved by the FDA in August 2018 for the treatment of HIV-1 in combination with other antiretrovirals in adult patients with no prior antiretroviral treatment experience.

Doravirine is available as a single agent (Pifeltro®) and as a once-daily fixed-dose combination tablet (Delstrigo®) containing doravirine, lamivudine (3TC) and tenofovir-DF (TDF).

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016